IRIX IRIDEX CORP

NEUTRAL Impact: 3/10 DEFA14A
Horizon immediate Filed Apr 24, 2026 Processed 1mo ago SEC 0002077096-26-000093
Proxy solicitation materials
Latest settled — T+20d
IRIX ▼ -3.70% at T+20d
NEUTRAL call ✗ call lost -3.70% · α vs SPY -8.66% · entry $1.08 → $1.04
Next anchor: T+60d in 5w
Last close $1.12 (close Jun 12) · +3.70% from $1.08 entry
Entry anchored
Apr 24, 03:58 PM ET
via Databento tick
T+1d
-3.70%
call -3.70% · α -3.22%
$1.04
settled 7w ago
T+5d
+0.93%
call +0.93% · α +0.53%
$1.09
settled 6w ago
T+20d
-3.70%
call -3.70% · α -8.66%
$1.04
settled 24d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

IRIDEX Corporation filed a definitive proxy statement (DEFA14A) for its 2026 annual stockholders' meeting, scheduled for June 12, 2026. The meeting will vote on the election of five director nominees, ratification of the company's auditor (BPM LLP), and an advisory vote on executive compensation. The board recommends voting FOR all proposals.

Actionable Insight

This is a routine annual meeting with no contested issues or activist involvement. Monitor the company's next earnings report for any updates on business performance or strategic direction.

Key Facts

  • IRIDEX Corporation (IRIX) is holding its annual stockholders' meeting on June 12, 2026.
  • Proposals include the election of five director nominees (Nick Chen, Beverly A. Huss, Patrick Mercer, William Moore, and Scott Shuda), ratification of BPM LLP as the independent auditor, and an advisory vote on executive compensation.
  • The Board of Directors recommends a vote FOR all nominees and proposals.
  • The filing is a routine annual proxy statement with no activist involvement or contested issues.

Financial Impact

No direct financial impact from the vote itself. The proposals are standard corporate governance items.

board compositionauditor relationshipexecutive compensation

Risk Factors

  • Low risk associated with the vote outcomes as all proposals are supported by management and are standard corporate governance items.
  • Potential shareholder concerns could arise if there is significant opposition to executive compensation (say-on-pay vote), but no such indication is present in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
86% bullish (7 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0002077096-26-000093
Document: 0002077096-26-000093-index-headers.html0002077096-26-000093
Document: 0002077096-26-000093-index.html0002077096-26-000093
Document: 0002077096-26-000093.txt0002077096-26-000093
5 reports for IRIX
Performance horizon
Filters
Rows
Reports for IRIX — sortable, filterable
Type Now
May 19, 2026
26d ago
8-K
NEUTRAL ★ 4/10
$1.00 $1.03▲ +3.00%▲ +1.76%$1.12 (+12.00%)
Apr 24, 2026
7w ago
DEFA14A
NEUTRAL ★ 3/10
$1.08 $1.09▲ +0.93%▲ +0.53%$1.12 (+3.70%)
Apr 7, 2026
9w ago
Press Release
NEUTRAL ★ 4/10
$1.03 $1.04▲ +0.97%▼ −2.55%$1.12 (+8.74%)
Mar 26, 2026
11w ago
Press Release
MIXED ★ 6/10
$0.9900 $1.00▲ +1.01%▼ −2.85%$1.12 (+13.13%)
Mar 12, 2026
13w ago
Press Release
NEUTRAL ★ 3/10
$1.30 $1.35▲ +3.85%▲ +5.96%$1.12 (−13.85%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 5h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access